Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents

3 Feb 2022

Abstract excerpt

PURPOSE: Translocation renal cell carcinoma (tRCC) is a subtype that occurs predominantly in children and young individuals. Metastatic tRCC occurring in young patients is more aggressive than that occurring in older patients, and there are still no effective therapies. Organoids can mimic original tissues and be assessed by high-throughput screening (HTS). We aimed to utilize patient-derived organoids and HTS to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Renal and related cancers
Share to Renal cell carcinoma treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35118587
DOI: 10.1007/s12094-021-02774-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agentsPMID 35118587Read ↗

An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying translocation RCCSemantic proximity Read ↗

An engineered tumor organoid model reveals cellular identity and signaling trajectories underlying SFPQ-TFE3 driven translocation RCCSemantic proximity Read ↗

Patient-derived renal cell carcinoma organoids for precision medicineSemantic proximity Read ↗

Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell CarcinomaSemantic proximity Read ↗

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular InsightsSemantic proximity Read ↗

The establishment of kidney cancer organoid line in drug testing.Semantic proximity Read ↗

Targeting cancer drug resistance utilizing organoid technologySemantic proximity Read ↗

Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinomaSemantic proximity Read ↗

Basal-shift transformation leads to EGFR therapy-resistance in human lung adenocarcinomaSemantic proximity Read ↗

Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancersSemantic proximity Read ↗

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read ↗

Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTENSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.